Dashboard
Manage Tickers

MRSN Mersana Therapeutics, Inc.

Nasdaq mersana.com


$ 10.74 nm (nm)    

Wednesday, 15-Oct-2025 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.22 $ 4.22 (0.71 %)
DIA $ 462.40 $ 0.00 (0 %)
SPY $ 665.02 nm (nm)
TLT $ 90.75 nm (nm)
GLD $ 387.24 $ 6.60 (1.73 %)
$ 10.3
$ 10.40
$ 9.65 x 5
$ 11.30 x 24
$ 9.59 - $ 11.15
$ 5.21 - $ 70.75
115,420
na
51.4M
$ 1.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-08-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-28-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

truist-securities-maintains-buy-on-mersana-therapeutics-adjusts-price-target-to-36-from-250-1-for-25-reverse-stock-split
Truist Securities Maintains Buy on Mersana...
08/14/2025 18:25:05

Truist Securities analyst Asthika Goonewardene maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy, Adjusts Target to $36 f...

guggenheim-maintains-buy-on-mersana-therapeutics-lowers-price-target-to-30
Guggenheim Maintains Buy on Mersana Therap...
08/14/2025 13:32:52

Guggenheim analyst Michael Schmidt maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and lowers the price target from ...

update-mersana-therapeutics-q2-adj-eps-408-misses-393-estimate-sales-3056m-miss-6363m-estimate
UPDATE: Mersana Therapeutics Q2 Adj. EPS $...
08/13/2025 14:06:24

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(4.08) per share which missed the analyst consensus estimate o...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

a-look-at-mersana-therapeuticss-upcoming-earnings-report
A Look at Mersana Therapeutics's Upcoming ...
08/12/2025 18:02:44

mersana-therapeutics-announces-1-for-25-reverse-stock-split-effective-5-pm-et-jul-25
Mersana Therapeutics Announces 1-for-25 Re...
07/24/2025 12:32:42

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
06/30/2025 21:06:29

mersana-therapeutics-announces-additional-interim-phase-1-clinical-data-for-emiltatug-ledadotin-b7-h4-directed-dolasynthen-adc
Mersana Therapeutics Announces Additional ...
06/02/2025 12:16:13

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses44% confirmed ORR (7 res...

truist-securities-maintains-buy-on-mersana-therapeutics-raises-price-target-to-10
Truist Securities Maintains Buy on Mersana...
05/16/2025 17:42:58

Truist Securities analyst Asthika Goonewardene maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and raises the price ...

guggenheim-reiterates-buy-on-mersana-therapeutics-maintains-5-price-target
Guggenheim Reiterates Buy on Mersana Thera...
05/16/2025 15:38:00

Guggenheim analyst Michael Schmidt reiterates Mersana Therapeutics (NASDAQ:MRSN) with a Buy and maintains $5 price target.

mersana-therapeutics-q1-eps-019-inline-sales-275m-miss-584m-estimate
Mersana Therapeutics Q1 EPS $(0.19), Inlin...
05/15/2025 11:04:15

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. Thi...

Core News & Articles
Earnings Scheduled For May 15, 2025
05/15/2025 08:32:23

an-overview-of-mersana-therapeuticss-earnings
An Overview of Mersana Therapeutics's Earn...
05/14/2025 21:01:34

mersana-therapeutics-implements-strategic-restructuring-and-reprioritization-plan-to-extend-cash-runway-advance-emi-le-xmt-1660
Mersana Therapeutics Implements Strategic ...
05/06/2025 11:09:31

Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-20...

mersana-therapeutics-announces-upcoming-emi-le-xmt-1660-oral-and-poster-presentations-at-asco-2025-annual-meeting
Mersana Therapeutics Announces Upcoming Em...
04/23/2025 14:15:18

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutic...

mersana-therapeutics-q4-eps-011-beats-015-estimate-sales-1636m-beat-771m-estimate
Mersana Therapeutics Q4 EPS $(0.11) Beats ...
03/03/2025 12:03:19

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-march-3-2025
Earnings Scheduled For March 3, 2025
03/03/2025 08:32:12

mersana-therapeutics-receives-nasdaq-non-compliance-notice
Mersana Therapeutics Receives Nasdaq Non-C...
02/28/2025 21:21:36

- SEC Filing

this-harrow-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Harrow Analyst Begins Coverage On A B...
02/06/2025 13:11:19

william-blair-initiates-coverage-on-mersana-therapeutics-with-outperform-rating
William Blair Initiates Coverage On Mersan...
02/06/2025 11:09:26

William Blair analyst Andy Hsieh initiates coverage on Mersana Therapeutics (NASDAQ:MRSN) with a Outperform rating.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION